Satraplatin for Patients With Metastatic Breast Cancer (MBC)

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Agennix
• Treatments: Satraplatin

Criteria

1. Has cytologically or pathologically confirmed breast cancer that is metastatic

2. Must have had prior HerceptinÒ therapy if patient has HER2+ (overexpressing) breast cancer. HER2 is considered overexpressed if it is 3+ by IHC or if the gene is amplified by Flourescence in situ hybridization (FISH)

3. Has had no more than 1 prior chemotherapy regimen for MBC

4. Has had no prior platinum-based therapy

5. Has an ECOG Performance Status (PS) 0-2